A strategic venture capital arm and innovation group of, a large health system with 13 hospitals in Michigan and Ohio is managing both a seed fund as well as a later-stage corporate venture fund, both dedicated to medtech and healthcare IT. In addition, the group also has an incubator and innovation group that looks to develop and integrate IP generated internally and externally that can be leveraged by the health system. Seed investments usually range from $100k – $500k with additional capital reserved for follow on investments, typically allocating up to $1.5M over the life of the investment. Later stage investments are usually in the range of $1M-$2M. The group is flexible in terms of structure but typically refers to convertible notes for seed deals and straight equity for later-stage investments. The firm may lead investments or invest with a syndicate and looks to be active in portfolio companies’ development and add value at the board level as well as through integration into the health system.
The firm is exclusively focused on the medtech and digital health/healthcare IT sectors. The group is fairly opportunistic in these areas, but looks for technologies that can be leveraged by the health system. Both pre-revenue and pre-FDA approval devices, as well as commercial/revenue-generating companies, will be considered. ProMedica has no preference for regulatory pathway and has a particular interest in the cardio space.
The firm has historically focused on startups in the midwestern United States, however, is looking more broadly and open to companies across the U.S. The group favors strong management teams that are open to working closely together.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply